Eidos Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
SAN FRANCISCO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX ) today announced that management will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Tuesday, October 2, 2018 at 3:30 p.m. ET. The conference will be held in New York, NY.
A live audio webcast of the presentation can be accessed through the Events & Presentations section of the company’s website at ir.eidostx.com. An archived replay of the webcast will be available on the company’s website for 90 days following the live presentation.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to treat this well-defined family of diseases at their collective source by stabilizing TTR. Our product candidate, AG10, an orally-administered small molecule designed to potently stabilize TTR, is a potentially best-in-class treatment aiming to halt the progression of ATTR diseases.
Founded in 2013, Eidos is led by a team of industry veterans who are responsible for developing over 30 molecules through IND applications and more than 10 approved drugs. Together with patients and physicians, we aim to bring a safe, effective and disease-modifying treatment for ATTR to market as quickly as possible.
Carolyn Hawley, Canale Communications, (619) 849-5382, email@example.com
Alex Gray, Burns McClellan, (212) 213-0006, firstname.lastname@example.org